Eosinophilic-lymphocytic myocarditis after smallpox vaccination

Joseph G. Murphy, R. Scott Wright, G. Keith Bruce, Larry M. Baddour, Michael A. Farrell, William D. Edwards, Hirohito Kita, Leslie T Jr. Cooper

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Smallpox is an eradicated viral disease that has re-emerged as a potential bioterrorism threat. Smallpox vaccination was historically the most effective defence measure against wild smallpox virus. The risk of myopericarditis after vaccination might limit this option. We report a case of biopsy-proven eosinophilic-lymphocytic myocarditis diagnosed in vivo with histological evidence for eosinophil-mediated cardiac myocyte necrosis shortly after smallpox vaccination. Furthermore, we report a beneficial haemodynamic response to high-dose corticosteroids. A better understanding of the aberrant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the future.

Original languageEnglish (US)
Pages (from-to)1378-1380
Number of pages3
JournalLancet
Volume362
Issue number9393
DOIs
StatePublished - Oct 25 2003

Fingerprint

Smallpox
Myocarditis
Vaccination
Variola virus
Smallpox Vaccine
Bioterrorism
Virus Diseases
Eosinophils
Cardiac Myocytes
Muscle Cells
Adrenal Cortex Hormones
Necrosis
Hemodynamics
Biopsy
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Murphy, J. G., Wright, R. S., Bruce, G. K., Baddour, L. M., Farrell, M. A., Edwards, W. D., ... Cooper, L. T. J. (2003). Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet, 362(9393), 1378-1380. https://doi.org/10.1016/S0140-6736(03)14635-1

Eosinophilic-lymphocytic myocarditis after smallpox vaccination. / Murphy, Joseph G.; Wright, R. Scott; Bruce, G. Keith; Baddour, Larry M.; Farrell, Michael A.; Edwards, William D.; Kita, Hirohito; Cooper, Leslie T Jr.

In: Lancet, Vol. 362, No. 9393, 25.10.2003, p. 1378-1380.

Research output: Contribution to journalArticle

Murphy, JG, Wright, RS, Bruce, GK, Baddour, LM, Farrell, MA, Edwards, WD, Kita, H & Cooper, LTJ 2003, 'Eosinophilic-lymphocytic myocarditis after smallpox vaccination', Lancet, vol. 362, no. 9393, pp. 1378-1380. https://doi.org/10.1016/S0140-6736(03)14635-1
Murphy JG, Wright RS, Bruce GK, Baddour LM, Farrell MA, Edwards WD et al. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet. 2003 Oct 25;362(9393):1378-1380. https://doi.org/10.1016/S0140-6736(03)14635-1
Murphy, Joseph G. ; Wright, R. Scott ; Bruce, G. Keith ; Baddour, Larry M. ; Farrell, Michael A. ; Edwards, William D. ; Kita, Hirohito ; Cooper, Leslie T Jr. / Eosinophilic-lymphocytic myocarditis after smallpox vaccination. In: Lancet. 2003 ; Vol. 362, No. 9393. pp. 1378-1380.
@article{d4fa0ccad2fc430fb822d6681c60d805,
title = "Eosinophilic-lymphocytic myocarditis after smallpox vaccination",
abstract = "Smallpox is an eradicated viral disease that has re-emerged as a potential bioterrorism threat. Smallpox vaccination was historically the most effective defence measure against wild smallpox virus. The risk of myopericarditis after vaccination might limit this option. We report a case of biopsy-proven eosinophilic-lymphocytic myocarditis diagnosed in vivo with histological evidence for eosinophil-mediated cardiac myocyte necrosis shortly after smallpox vaccination. Furthermore, we report a beneficial haemodynamic response to high-dose corticosteroids. A better understanding of the aberrant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the future.",
author = "Murphy, {Joseph G.} and Wright, {R. Scott} and Bruce, {G. Keith} and Baddour, {Larry M.} and Farrell, {Michael A.} and Edwards, {William D.} and Hirohito Kita and Cooper, {Leslie T Jr.}",
year = "2003",
month = "10",
day = "25",
doi = "10.1016/S0140-6736(03)14635-1",
language = "English (US)",
volume = "362",
pages = "1378--1380",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9393",

}

TY - JOUR

T1 - Eosinophilic-lymphocytic myocarditis after smallpox vaccination

AU - Murphy, Joseph G.

AU - Wright, R. Scott

AU - Bruce, G. Keith

AU - Baddour, Larry M.

AU - Farrell, Michael A.

AU - Edwards, William D.

AU - Kita, Hirohito

AU - Cooper, Leslie T Jr.

PY - 2003/10/25

Y1 - 2003/10/25

N2 - Smallpox is an eradicated viral disease that has re-emerged as a potential bioterrorism threat. Smallpox vaccination was historically the most effective defence measure against wild smallpox virus. The risk of myopericarditis after vaccination might limit this option. We report a case of biopsy-proven eosinophilic-lymphocytic myocarditis diagnosed in vivo with histological evidence for eosinophil-mediated cardiac myocyte necrosis shortly after smallpox vaccination. Furthermore, we report a beneficial haemodynamic response to high-dose corticosteroids. A better understanding of the aberrant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the future.

AB - Smallpox is an eradicated viral disease that has re-emerged as a potential bioterrorism threat. Smallpox vaccination was historically the most effective defence measure against wild smallpox virus. The risk of myopericarditis after vaccination might limit this option. We report a case of biopsy-proven eosinophilic-lymphocytic myocarditis diagnosed in vivo with histological evidence for eosinophil-mediated cardiac myocyte necrosis shortly after smallpox vaccination. Furthermore, we report a beneficial haemodynamic response to high-dose corticosteroids. A better understanding of the aberrant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the future.

UR - http://www.scopus.com/inward/record.url?scp=0242317388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242317388&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14635-1

DO - 10.1016/S0140-6736(03)14635-1

M3 - Article

C2 - 14585641

AN - SCOPUS:0242317388

VL - 362

SP - 1378

EP - 1380

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9393

ER -